Buprenorphine And Naloxone Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Buprenorphine And Naloxone Market report segments the industry into By Type (Branded, Generics), By Formulation (Sublingual Tablets, Sublingual Films), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Get five years of historical data alongside five-year market forecasts.

Buprenorphine And Naloxone Market Size

Compare market size and growth of Buprenorphine And Naloxone Market with other markets in Healthcare Industry

Buprenorphine And Naloxone Market Analysis

The Buprenorphine And Naloxone Market size is estimated at USD 4.93 billion in 2025, and is expected to reach USD 6.06 billion by 2030, at a CAGR of 4.23% during the forecast period (2025-2030).

The market growth is driven by increasing substance use disorders, the advantages of using buprenorphine and naloxone, and the rising prevalence of acute and chronic pain disorders.

For instance, according to an article published by the StatPearls Journal in April 2023, every year, opioid use disorders affect over 16 million people worldwide and more than 2.1 million people in the United States. Therefore, the global increase in opioid addiction and dependence has created a significant demand for effective treatments.

Buprenorphine and naloxone combination drugs have emerged as popular medications for opioid addiction treatment due to the several advantages associated with using combination drugs. According to a June 2022 article from BioMed Central Ltd, buprenorphine and naloxone are the primary medications for individuals experiencing an opioid overdose. Buprenorphine reduces opioid use and cravings, prevents withdrawal symptoms, and limits the risk of opioid overdose. Naloxone is a life-saving medication that can be administered to reverse an opioid overdose.

Similarly, according to a report published by the DovePress Journal in March 2024, the increasing prevalence of chronic pain and the risks associated with opioid use have highlighted the need for safer alternatives in pain management. Buprenorphine's unique mechanism of action, lower risk of overdose, and clinical efficacy in various formulations have led to its recommendation as a first-line treatment for chronic pain by major US health agencies. These factors have driven greater adoption and demand, thereby propelling the growth of the buprenorphine and naloxone market.

In conclusion, the growing prevalence of substance use disorders and chronic pain, combined with the advantages of buprenorphine and naloxone in providing safer, effective treatment options, has significantly driven the adoption of these combination drugs.

However, stigma and misconceptions regarding the use of suboxone, along with stringent regulatory constraints, are major restraints in the market.

Buprenorphine And Naloxone Industry Overview

The buprenorphine and naloxone market is moderately consolidated due to the presence of a limited number of companies that manufacture and distribute buprenorphine and naloxone drugs. The competitive landscape includes an analysis of several international and local companies that hold market shares and are well known, including Indivior PLC, Viatris Inc. (Mylan Inc.), Sandoz AG, Hikma Pharmaceuticals PLC, and Dr. Reddy's Laboratories Ltd.

Buprenorphine And Naloxone Market Leaders

  1. Indivior PLC

  2. Viatris Inc. (Mylan Inc.)

  3. Sandoz AG

  4. Dr. Reddy's Laboratories Ltd.

  5. Hikma Pharmaceuticals PLC

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Buprenorphine And Naloxone Market News

  • May 2024: Purdue Pharma L.P. partnered with MMCAP Infuse to supply buprenorphine and naloxone tablets CIII (generic Suboxone) at a reduced cost to correctional facilities. This initiative aims to provide medication for opioid use disorder (MOUD) to incarcerated individuals struggling with opioid addiction.
  • December 2023: Indivior PLC entered a settlement agreement with Actavis Laboratories UT Inc., a Teva Pharmaceuticals subsidiary, to resolve patent disputes over Actavis’s abbreviated new drug application (ANDA) for a generic buprenorphine and naloxone sublingual film.

Buprenorphine And Naloxone Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Substance Use Disorders
    • 4.2.2 Various Advantages Associated with the Use of Suboxone
  • 4.3 Market Restraints
    • 4.3.1 Stigma and Misconceptions Regarding the Use of Suboxone
    • 4.3.2 Stringent Regulatory Constraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value-USD)

  • 5.1 By Type
    • 5.1.1 Branded
    • 5.1.2 Generics
  • 5.2 By Formulation
    • 5.2.1 Sublingual Tablets
    • 5.2.2 Sublingual Films
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Indivior PLC
    • 6.1.2 Viatris Inc. (Mylan Inc.)
    • 6.1.3 Sandoz AG
    • 6.1.4 Alvogen Inc.
    • 6.1.5 Dr. Reddy's Laboratories Ltd
    • 6.1.6 Hikma Pharmaceuticals PLC
    • 6.1.7 Teva Pharmaceutical Industries Ltd
    • 6.1.8 Amneal Pharmaceuticals LLC
    • 6.1.9 Mallinckrodt Pharmaceuticals
    • 6.1.10 Lannett Company Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Buprenorphine And Naloxone Industry Segmentation

As per the scope of the report, buprenorphine and naloxone are a fixed-dose combination that is used for the treatment of opioid addiction and pain management. The drug is mainly given through the sublingual route through tablets and films. The buprenorphine and naloxone market is segmented by type, formulation, distribution channel, and geography. The type segment is divided into branded and generics. The formulation segment is bifurcated into sublingual tablets and sublingual films. The distribution channel is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market size and forecasts in value (in USD) for the above segments.

By Type Branded
Generics
By Formulation Sublingual Tablets
Sublingual Films
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Type
Branded
Generics
By Formulation
Sublingual Tablets
Sublingual Films
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Buprenorphine And Naloxone Market Research Faqs

How big is the Buprenorphine And Naloxone Market?

The Buprenorphine And Naloxone Market size is expected to reach USD 4.93 billion in 2025 and grow at a CAGR of 4.23% to reach USD 6.06 billion by 2030.

What is the current Buprenorphine And Naloxone Market size?

In 2025, the Buprenorphine And Naloxone Market size is expected to reach USD 4.93 billion.

Who are the key players in Buprenorphine And Naloxone Market?

Indivior PLC, Viatris Inc. (Mylan Inc.), Sandoz AG, Dr. Reddy's Laboratories Ltd. and Hikma Pharmaceuticals PLC are the major companies operating in the Buprenorphine And Naloxone Market.

Which is the fastest growing region in Buprenorphine And Naloxone Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Buprenorphine And Naloxone Market?

In 2025, the North America accounts for the largest market share in Buprenorphine And Naloxone Market.

What years does this Buprenorphine And Naloxone Market cover, and what was the market size in 2024?

In 2024, the Buprenorphine And Naloxone Market size was estimated at USD 4.72 billion. The report covers the Buprenorphine And Naloxone Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Buprenorphine And Naloxone Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on: March 31, 2025

Buprenorphine And Naloxone Industry Report

Statistics for the 2025 Buprenorphine And Naloxone market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Buprenorphine And Naloxone analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.